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Abstract
Some anti-cancer drugs, including those that alter microtubule dynamics target mitotic cells and induce apoptosis in some
cell types. However, such drugs elicit protective responses in other cell types allowing cells to escape from drug-induced
mitotic inhibition. Cells with a faulty protective mechanism undergo defective mitosis, leading to genome instability. Brd4 is
a double bromodomain protein that remains on chromosomes during mitosis. However, Brd4 is released from mitotic
chromosomes when cells are exposed to anti-mitotic drugs including nocodazole. Neither the mechanisms, nor the
biological significance of drug-induced Brd4 release has been fully understood. We found that deletion of the internal C-
terminal region abolished nocodazole induced Brd4 release from mouse P19 cells. Furthermore, cells expressing truncated
Brd4, unable to dissociate from chromosomes were blocked from mitotic progression and failed to complete cell division.
We also found that pharmacological and peptide inhibitors of the c-jun-N-terminal kinases (JNK) pathway, but not inhibitors
of other MAP kinases, prevented release of Brd4 from chromosomes. The JNK inhibitor that blocked Brd4 release also
blocked mitotic progression. Further supporting the role of JNK in Brd4 release, JNK2–/– embryonic fibroblasts were
defective in Brd4 release and sustained greater inhibition of cell growth after nocodazole treatment. In sum, activation of
JNK pathway triggers release of Brd4 from chromosomes upon nocodazole treatment, which mediates a protective
response designed to minimize drug-induced mitotic stress.
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Introduction
Anti-mitotic drugs that interfere with microtubule dynamics are
used in cancer chemotherapy [1,2]. These drugs, such as
nocodazole, colcemid and taxol arrest cells at prometaphase,
and induce rapid apoptosis in some cancer cells. However, these
drugs also prompt activation of a protective mechanism in other
cells, allowing cells to survive and go through mitosis [3]. A
reversible anti-tubulin agent, nocodazole has been extensively
investigated to study protective responses against mitotic stress,
because nocodazole treated cells, upon drug removal, resume
mitosis and produce viable daughter cells, although nocodazole
treatment delays mitotic progression and increases aneuploidy and
genome instability [1,4].
Anti-mitotic drugs activate mitogen activated kinase (MAPK)
pathways that regulate various stress responses, resulting in cell
survival and/or death [5,6,7]. The c-jun NH2 terminal kinases
(JNK), among other MAPKs are activated by anti-tubulin drugs in
many cancer cells [6,7,8,9,10,11]. Furthermore, there is evidence
indicating that JNK is activated during the normal course of
mitosis and plays a role in some stages of mitosis
[10,12,13,14,15,16]. Among three JNKs, JNK1 and JNK2 are
ubiquitously expressed and thought to have distinct and over-
lapping roles in diverse settings. JNK3 is expressed in a brain
specific manner [17,18]. JNK appears to manifest complex,
seemingly opposite biological activities in cancer and normal cells
[19]. For example, JNK is associated with cell death as well as cell
survival, since it elicits pro- and anti-apoptotic activities in
a context dependent manner. Similarly, JNK is reported to have
pro- and anti-oncogenic activities depending on model systems.
Brd4 is a member of the conserved BET family [20]. It binds
to acetylated histone H3 and H4 through the two bromodomains
present in the N-terminal region [21,22]. As a salient feature of
the BET family, Brd4 remains on chromosomes during mitosis in
mammalian and zebrafish cells [21,22,23,24,25]. The retention
of Brd4 and other BET proteins on mitotic chromosomes is
unusual, given that most of general and specific transcription
factors, even those with a bromodomain are released from
chromatin during mitosis, leading to the general shut down of
transcription [26,27]. Besides the BET proteins, there are other
proteins that remain bound on chromosomes during mitosis that
act in epigenetic marking [28,29]. Relevant to this, we found that
Brd4, by staying on mitotic chromosomes, marks transcription
start sites of genes programmed for early postmitoic transcription
[30]. During interphase, Brd4 recruits a transcription elongation
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thus regulating diverse biological activities [31,32,33,34,35,36].
We previously showed that a variety of anti-tubulin drugs,
including nocodazole, trigger complete release of Brd4 from
mitotic chromosomes [37]. In that paper, we also reported
evidence that Brd4 release is linked to cells’ recovery from drug-
induced mitotic inhibition.
The aim of this study was to further investigate the potential link
between Brd4 release and mitotic stress responses. To this end we
addressed signaling pathways involved in Brd4 release and the
functional significance of Brd4 release. Here we show by testing
MAPK inhibitors, that activation of the JNK pathway is a major
mechanism of nocodazole induced Brd4 release. Deletion analysis
found that the C-terminal region of Brd4, unrelated to the
bromodomains mediated its release. In line with the role for JNK,
cells treated with a JNK inhibitor sustained greater impairment in
mitotic progression after nocodazole treatment than without
inhibitor. Matching with this result, cells expressing a Brd4 C-
terminal deletion were defective in cell division after drug
treatment. In addition, JNK2–/– embryonic fibroblasts were
defective in drug-induced Brd4 release and endured greater
growth inhibition than wild type cells. Together, our study
supports the view that Brd4 release is triggered upon JNK
activation, which leads to a protective response against drug-
induced mitotic inhibition.
Results
Anti-tubulin and Other Anti-mitotic Drugs Trigger
Release of Brd4 from Chromosomes
Persistent retention of Brd4 on mitotic chromosomes is a major
feature of Brd4 in normal untreated cells. However, Brd4 is
released from chromosomes upon treatment with anti-tubulin
drugs [37]. Figure 1A shows live cell images of P19 cells expressing
Brd4 fused to the green fluorescent protein (GFP-Brd4) with or
without treatment with nocodazole. In untreated cells, the entire
GFP-Brd4 localized to mitotic chromosomes (Figure S1A). In
contrast, in nocodazole treated cells, Brd4 was entirely released
from chromosomes into the outer space. In cells expressing free
GFP, tested as a control, fluorescent signals were outside of
chromosomes, as expected. Likewise, GFP-Brd4 was released from
mitotic chromosomes when cells were exposed to other anti-
tubulin agents, paclitaxel and colcemid (Figure S1B). Differential
salt extraction experiments in Figure 1B showed that upon
treatment with anti-tubulin agents Brd4 was eluted at salt
concentrations lower than those observed in untreated cells. As
shown in Figure 1B, the total amounts of Brd4 were unaltered by
anti-tubulin drugs. These data provide microscopic and bio-
chemical evidence that Brd4 is released upon treatment with anti-
tubulin agents.
Since these agents inhibit mitotic spindle formation, we asked
whether Brd4 is released as a result of disruption of spindle
formation. It has been shown that these drugs at low concentra-
tions do not break spindle mass formation, while arresting cells at
prometaphase [2]. In Figure 1C, we tested the effect of nocodazole
at 5 and 10 ng/ml, the doses lower than those required for
disruption of spindle formation. At 5 ng/ml of nocodazole, Brd4
was partially released from mitotic chromosomes, while it was
completely released at 10 ng/ml as verified by the separate
localization of Brd4 and DNA (see the merge image). However,
the architecture of mitotic spindles was well preserved at these
concentrations. As expected, at higher nocodazole concentrations
(20 and 50 ng/ml), spindle structures were altered or no longer
recognizable. Data in Figure 1D show that mitotic arrest occurred
both at 10 and 20 ng/ml of nocodazole treatment, albeit less
efficiently than at 50 ng/ml. Thus, Brd4 release appeared not
directly linked to spindle assembly disruption, suggesting the
existence of other mechanisms controlling Brd4 release. To
address whether Brd4 is released by anti-mitotic drugs that do
not affect microtubule dynamics, we tested monasterol and
Blebbistatin, small molecule inhibitors that impede mitotic
processes by different mechanisms [38,39]. Monasterol arrests
cells at prometaphase by inhibiting kinesin, while blebbistatin
blocks cytokinesis, a post anaphase event producing two daughter
cells. Data in Figure 1E show that both agents also released Brd4
completely from chromosomes. Thus, release of Brd4 is a physi-
ological response to a broad range of anti-mitotic drugs.
Brd4 Release is Mediated by the Internal C-terminal
Region
To assess domains within Brd4 that are required for
nocodazole-induced Brd4 release, Brd4 deletions fused to GFP
were expressed in P19 cells and tested for their localization after
nocodazole treatment (see Figure 2A for a diagram of Brd4
deletion). Figure 2B illustrates representative images of the
localization of each Brd4 deletion with (top) or without nocodazole
treatment (bottom). Full length GFP-Brd4, while localizing to
mitotic chromosomes in untreated cells, was released from
chromosomes after treatment. Free GFP localized outside of
chromosomes irrespective of drug treatment. In contrast, GFP-
DET&C and GFP-DC were not released from chromosomes by
the same treatment. These constructs lack the bulk of the internal
C-terminal region, but retained the extreme C-terminal fragment
from aa.1317 to aa.1400 (gray box in Figure 2A). The
bromodomain deletions, DI, DII and DI & II did not localize to
mitotic chromosomes and remained outside of the chromosomes
with and without nocodazole treatment. The results with
bromodomain deletions were expected, since binding of Brd4 to
chromosomes depends on the bromodomains [21]. To quantify
microscopic data, we counted approximately 200 cells for each
construct, and confirmed that the images in Figure 2B represent
more than 90% of cells (see summary in Figure 2A, right). These
data show that the C-terminal region between aa. 700 to aa.1316
is critical for nocodazole induced Brd4 release. This region is
relatively divergent among orthologues in different species, but
contains a number of small motifs that are well preserved [22,25].
In keeping with these results, Brd4 with an additional deletion
lacking the extreme C-terminal fragment also failed to dissociate
from chromosomes (data not shown). The requirement of the C-
terminal region, not the bromodomains, indicates that nocodazole
induced Brd4 release was not due to a change in Brd4’s acetyl
histone binding activity.
Brd4 Release Helps to Relieve Drug-induced Mitotic
Inhibition
To address the biological meaning of Brd4 release, we tested
whether cells expressing GFP-DC were capable of going through
mitosis after nocodazole treatment. In Figure 3A, cells expressing
GFP-full length Brd4, free GFP or GFP-DC were first treated with
nocodazole for 4 h, then nocodazole was removed by extensive
wash. Cells were then allowed to proceed through mitosis in the
following60 mininfresh,drugfreemedia.InFigure3A,thenumber
of mitotic cells (cells in anaphase and telophase) that carried GFP
signals was counted at 15 min intervals. Cells expressing full length
GFP-Brd4 and free GFP began entering anaphase/telophase at
30 min.Thenumberofdividingcellspeakedat45 minwheremore
than 50% of cells were in anaphase/telophase. Figure S2A is
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e34719Figure 1. Anti-mitotic drugs induce release of Brd4 from mitotic chromosomes. A. P19 cells transfected with vectors for GFP alone or full
length GFP-Brd4 (GFP-FL-Brd4) were treated with nocodazole (50 ng/ml) for 4 h, and GFP signals were viewed by confocal and differential
interference contrast (DIC) microscopy. B. Differential salt extraction. Mitotic cells treated with nocodazole, paclitaxel or colcemid (100 ng/ml each) for
4 h were extracted with indicated concentrations of KCl. Twenty mg of extracts were immunoblotted with antibody for Brd4 or TFIIB. In the right
panel, total Brd4 and TFIIB extracted at 400 mM KCl were detected as above. C. Cells were treated with indicated concentrations of nocodazole for
4 h, and mitotic cells were immunostained for endogenous Brd4 and a-tubulin. DNA was stained by Hoechst33324. D. Mitotic indices of nocodazole
treated cells. Cells in prometaphase or anaphase/telophase were microscopically inspected. Approximately 200 cells were examined for each data
point. E. Cells were treated with 100 mM of monastrol or 50 mM of blebbistatin for 4 h and localization of Brd4 was examined by immunostaining as in
Figure 1C.
doi:10.1371/journal.pone.0034719.g001
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on mitotic chromosomes after nocodazole removal. By 60 min,
mitosis was completed and most cells were in G1 phase. In contrast,
fewer GFP-DC expressing cells progressed to mitosis: only about
30% of cells were in anaphase/telophase at 45 min. By 60 min,
virtually no mitotic cells were found in GFP-DC cells. These data
suggest that Brd4 release is important for successful progression of
mitosis after nocodazole treatment. To further assess a step affected
by GFP-DC, we tested phosphorylation of histone H3 at Serine 10
anddegradationofcyclinB1.Theseeventsdenoteentryintomitosis
and progression through metaphase [40,41,42]. Immunoblot data
in Figure 3B showed that H3 S10 phosphorylation occurred in cells
expressing GFP-DC in a manner similar to those expressing GFP or
full length GFP-Brd4. Similarly, cyclin B1 protein levels fell at 40 to
60 min,irrespectiveoftheexpressionoffulllengthBrd4orGFP-DC
(Figure 3C). These results indicate that expression of GFP-DC did
not interfere with entry into mitosis, nor the initiation of exit from
mitosis, but inhibited a subsequent step at anaphase/telophase.
Nocodazole treatment causes chromosomal missegregation,
leading to genome instability in some cells [4]. Since anaphase/
telophase is a stage when chromosomes begin to be segregated and
partitioned into daughter cells, we examined whether GFP-DC
expression affects chromosomal segregation. Microscopic images
in Figure 3D and S2B illustrate lagging chromosomes and
chromosomal bridges, representative defects noted for nocodazole
treatment [4]. As shown in Figure 3E, the number of cells
exhibiting defective chromosomal segregation was higher in cells
expressing GFP-DC than those expressing full length GFP-Brd4 or
free GFP. Nearly 60% of cells expressing GFP-DC were found to
have chromosomal missegregation, the majority of them showing
lagging chromosomes. About 20% of cells expressing free GFP or
full length GFP-Brd4 also had abnormal chromosomal segrega-
tion, as expected [4].
Extensive mitotic detects observed with GFP-DC was somewhat
surprising, given that these cells also expressed the endogenous,
full length Brd4. The defect observed with GFP-DC may be
attributed to a dominant negative activity of GFP-DC: we found
that GFP-DC, but not full length GFP-Brd4, blocked release of full
length Flag-tagged Brd4 from chromosomes (Figure S3). This
dominant negative effect may be attributed to the interaction of
full length Brd4 with DC that may occur through the
bromodomains or by indirect mechanisms [43,44,45]. Thus, the
marked defects observed with GFP-DC may partly be due to the
concurrent inhibition of release of full length Brd4.
Nocodazole-induced Brd4 Release Depends on
Activation of the JNK Pathway
Anti-mitotic drugs activate mitogen activated kinase (MAPK)
pathways, including those for extracellular signal regulated kinases
(ERK), p38, and JNK [5,6,7,8]. To investigate whether a specific
MAPK pathway is involved in nocodazole-induced Brd4 release,
we tested pharmacological inhibitors of MAPKs. PD98059 and
U0126 inhibit activity of MEK in the ERK pathways, and
SB203580 inhibits p38 MAP kinase. SP600125 has been used as
a specific inhibitor of JNK [46,47,48,49]. These inhibitors were
added prior to nocodazole addition and present during the next
4 h of nocodazole treatment. Localization of Brd4 was examined
at the end of this treatment by immunostaining (Figure 4A). The
inhibitors for MEK and p38 MAP kinase pathways had no effects
on nocodazole-induced Brd4 release. In contrast, the JNK
inhibitor, SP600125 completely blocked Brd4 release at concen-
trations ranging from 5 mMt o3 0mM (Figure 4A, Figure S4A).
The effect of the JNK inhibitor was particularly evident in the
merge images where Brd4 colocalized with DNA, but not tubulin.
On the other hand, in cells treated with other inhibitors and
untreated cells, Brd4 showed an opposite pattern of colocalization,
i,e., colocalizing with tubulin, but not with DNA. Of more than
200 mitotic cells inspected, approximately 85% of SP600125
treated cells showed Brd4 on chromosomes. Despite that the JNK
inhibitor has a striking effect on Brd4 localization, it did not
change nocodazole-induced spindle disruption (see a-tubulin
staining), consistent with the earlier data in Figure 1C. In the
absence of nocodazole, the inhibitor did not change Brd4’s
localization to mitotic chromosomes, indicating that the inhibitor
altered the movement of Brd4 only in nocodazole treated cells, but
not untreated mitotic cells (Figure S4B). These data gave a first
clue for the role of JNK pathways in Brd4 release. The inhibition
of Brd4 release by SP600125 was further substantiated by
differential salt extraction data, where the inhibitor reduced the
amounts of Brd4 extracted at KCl concentrations ranging from
Figure 2. Domain analysis for nocodazole induced Brd4
release. A. Left: Diagram of Brd4 deletions. BDI and BDII represent
bromodomains, ET stands for the ET domain. DET and DC are devoid of
the internal C-terminal region, but contain the extreme C-terminal 83
amino acids. Right: A summary of nocodazole induced Brd4 release. +
indicates retention of Brd4 on mitotic chromosomes, while– indicates
Brd4 release after nocodazole treatment. B. Cells expressing free GFP,
GFP-full length (FL) Brd4 or indicated deletions were treated with
nocodazole (top panel) or vehicle alone (bottom panel) for 4 h and
localization of GFP and chromosomes (DNA) was examined by
microscopy. Approximately 200 mitotic cells were inspected for each
deletion construct. After nocodazole treatment, more than 90% cells
expressing DET&C and DC retained GFP signals on chromosomes, while
less than 5% of full length Brd4 did so. Bromodomain deletions (DI, DII,
and DI&II) and Free GFP did not localize to chromosomes, irrespective
of drug treatment.
doi:10.1371/journal.pone.0034719.g002
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a control, was not affected by SP600125. Similarly, the total levels
of Brd4 or TFIIB were unaltered by SP600125 (Figure 4B, right).
Since these data pointed to a role for JNK activation in Brd4
release, we next tested whether JNK was activated after
nocodazole treatment in these cells. Immunoblot analysis with
antibody against phosphorylated JNK showed a marked increase
in phosphorylated JNK after nocodazole treatment, while total
JNK levels were unchanged by the drug treatment (Figure 4C).
Because SP600125 was added before nocodazole treatment in
above experiments, we next examined whether SP600125 inhibits
Brd4 release when added after nocodazole treatment. In Figure 4D
andS4C,cellsweretreatedwithnocodazolefor3 handthentreated
with SP600125 for the remaining 1 h. The delayed addition of the
inhibitor also caused inhibition in Brd4 release, indicating that the
inhibitor exerts its effect rapidly, even after nocodazole treatment.
To further corroborate the role of JNK, another JNK inhibitor,
JNKI-1 was tested [50]. This inhibitor is a cell penetrable peptide
derivedfromtheJNKinteractingprotein1/Islet-brain1(JIP-1/IB1)
that blocks binding of substrates to the enzymes. As shown in
Figure 4E and S4D, JNKI-1 also inhibited nocodazole-induced
Brd4 release. Similar to SP600125, spindle disruption was not
affectedbytheinhibitor.Asexpected,controlpeptidedidnotinhibit
nocodazole-inducedBrd4release.Together,thesedataindicatethat
activation of the JNK pathway accounts for nocodazole-induced
Brd4 release.
In light of the data in Figure 3A showing that inhibition of Brd4
release leads to inhibition of mitosis, we surmised that inhibition of
JNK activity may also cause inhibition of mitotic progression. To
test this possibility, cells were pretreated with 5 or 10 mMo f
SP600125 followed by 4 h of nocodazole treatment. Then
nocodazole was removed from media allowing cells to proceed
through mitosis. In Figure 4F, mitotic progression was quantified
by counting anaphase and telophase cells at various time points. As
observed in Figure 3A, nocodazole treated cells without inhibitor
began dividing at 30 min. The number of dividing cells peaked at
45 min where more than 60% of cells were in cell division (open
circle in Figure 4F). In contrast, the number of dividing cells was
markedly reduced in cells treated with SP600125 at 5 mM and
10 mM: in the presence of the inhibitor, only 20 to 33% of cells
were in cell division (Closed symbols in Figure 4F). Thus, the
inability of releasing Brd4 from chromosome again correlated with
the inhibition of cell division. Together, these data indicate that
JNK activation triggers Brd4 release, which prompts a protective
response against nocodazole induced mitotic inhibition.
JNK2–/– Fibroblasts are Defective in Brd4 Release and
Sustain Growth Inhibition After Nocodazole Treatment
To further investigate the role of JNK in Brd4 release, we next
tested embryonic fibroblasts (MEFs) from JNK1–/– and JNK2–/–
mice [51,52]. In Figure 5A, JNK1–/–, JNK2–/– and wild type
Figure 3. The Brd4 internal deletion (DC) inhibits mitotic progression after nocodazole treatment. A. Cells expressing free GFP, GFP-full
length (FL) Brd4, or GFP-DC were treated with nocodazole for 4 h, washed and then allowed to proceed to anaphase and telophase in media without
nocodazole for indicated times (min). The number of dividing cells with GFP signals were counted by microscopic inspection, and expressed as the
percentage of total GFP positive cells. Similar experiments were performed for four times where mitotic cells with GFP-DC were consistently lower
than those with GFP alone or GFP-FL Brd4. Extracts from cells expressing free GFP, GFP-FLBrd4, or GFPDC treated with nocodazole were
immunoblotted for H3 phosphorylated at S10. a-tubulin was tested as a loading control. *denotes p,0.005. B. Extracts from cells expressing above
constructs were treated with nocodazole, and allowed to proceed through mitosis without nocodazole for indicated times (min), and immunoblotted
for cyclin B1 and a-tubulin. C. Cells expressing above constructs were treated with nocodazole, washed and allowed to reach anaphase/telophase.
Cells expressing GFP-DC were stained with Hoechst33324 to view chromosomal segregation. The images represent a typical lagging chromosome
and chromosomal bridge, respectively. D. Mitotic cells expressing free GFP, GFP-FL-Brd4 or GFP-DC were inspected for chromosomal missegregation.
Values represent the percentage of total dividing cells (approximately 200 cells per group).
doi:10.1371/journal.pone.0034719.g003
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nous Brd4 was examined by immunostaining. These experiments
were performed using cells within four passages after primary
culture. In untreated cells, Brd4 localized to mitotic chromosomes
in all three cells. In wild type cells, Brd4 was completely released
upon nocodazole addition. However, a large fraction of JNK2–/–
Figure 4. JNK inhibitors block nocodazole induced Brd4 release and prevent mitotic progression. A. SP600125 (10 mM), PD98059, U0126
or SB20458 (100 mM) was added to cells 30 min or 2 h prior to nocodazole addition, respectively. The inhibitors were present during the subsequent
4 h of nocodazole treatment (see top for the treatment scheme). Representative immunostaining data are shown below, depicting the localization of
endogenous Brd4 and a-tubulin. Of about 200 SP600125 treated cells inspected, more than 90% of cells retained Brd4 on mitotic chromosomes after
nocodazole treatment. B. Cells were treated with SP600125 and nocodazole as above and tested for differential salt extraction as in Figure 1B. C.
Extracts from cells treated with or without nocodazole were blotted against total JNK or phosphorylated JNK. a-tubulin was tested as a loading
control. The right lane represents samples from mitotic cells collected by mitotic shake-off. D. SP600125 was added to cells that had been treated
with nocodazole for 3 h. Cells were incubated for an additional 1 h in the presence of the inhibitor and nocodazole before harvest, and
immunostained as in Figure 4A. Of 200 mitotic cells counted, about 85% of cells treated with SP600125 and nocodazole retained Brd4 on
chromosomes, while less than 10% of cells treated with nocodazole alone did. E. Cells were incubated with of control or JNKI-1 peptides (5 mM) for
30 min prior to 4 h nocodazole treatment. About 80% of JNKI-1 treated cells did not release Brd4 from chromosomes, while 90% of cells treated with
the control peptide released Brd4. F. Cells treated with SP600125 and nocodazole using the scheme in Figure 4A were allowed to proceed through
mitosis for indicated times (min), and stained with Hoechst33324 and cells in anaphase/telophase were counted as dividing cells. The values
represent the average of three determinations +/– S.D. * indicates p,0.005.
doi:10.1371/journal.pone.0034719.g004
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On the other hand, fewer JNK1–/– cells retained Brd4. Spindle
formation was completely disrupted in all three cells, confirming
nocodazole action in these cells. Data in Figure 5B show the
number of mitotic cells that failed to release Brd4 after nocodazole
treatment. More than 40% of JNK2–/– cells failed to release Brd4
from chromosomes upon drug treatment, while only ,15% of
JNK1–/– cells and ,8% of wild type cells, respectively failed to
release Brd4. These data indicate that JNK2 plays a somewhat
dominant role over JNK1 in releasing Brd4, although both
contribute to it.
To study whether the absence of JNK1 or JNK2 compromises
recovery from drug-induced mitotic inhibition, nocodazole treated
JNK1–/– and JNK2–/– cells were allowed to proceed for 36 h
and viable cell yields were assessed at the end of culture
(Figure 5C). In JNK2–/– cells, nocodazole treatment at 25 ng/
ml caused approximately a 36% reduction in cell yields relative to
untreated cells. On the other hand the same treatment led to
a more modest reduction in JNK1–/– cells (12–17%). As
expected, wild type cells showed the least reduction in viable cell
yields. Similarly at a higher nocodazole concentration (100 ng/
ml), viable cell yields were the lowest in JNK2–/– cells, the
intermediate in JNK1–/– and the highest in wild type cells. These
data support the idea that although both JNKs contribute, JNK2
plays a greater role in releasing Brd4 as well as restoring mitotic
progression after nocodazole treatment than JNK1.
Discussion
In this study we addressed the mechanism by which anti-mitotic
drugs triggers release of Brd4 from mitotic chromosomes. Analysis
of deletion constructs found that the internal region from aa. 670
to aa.1317 within the C-terminal domain is required for Brd4
release. This region is separate from the conserved bromodomains
and the ET domain, and carries a histidine tract, several glutamine
repeats and is rich in serine and proline [22,25]. Since this region
excludes the binding site for P-TEFb, important for transcription
elongation, nocodazole induced Brd4 release is unrelated to Brd4’s
interaction with P-TEFb [53]. In line with this conclusion, the
interaction of Brd4 with P-TEFb is limited to interphase, in that
Figure 5. JNK2–/–MEFs are impaired in Brd4 release after nocodazole treatment. A. Wild type, JNK1–/– and JNK2–/– MEFs were treated
with nocodazole at 25 ng/ml for 4 h. Endogenous Brd4, a-tubulin and DNA were localized by immunostaining as above. A greater number of
JNK2–/– cells failed to release Brd4 after nocodazole treatment than wild type and JNK1–/– cells. B. Mitotic cells that failed to release Brd4 after
nocodazole treatment in above experiments were quantified and expressed as the percentage of total mitotic cells. The values represent the average
of three determinations +/– S.D. C. MEFs were treated with indicated concentrations of nocodazole for 6 h, washed and allowed to proceed for 36 h
in culture, and total viable cell yields were determined. The values represent the average of three separate experiments +/– S.D. * indicates p,0.005.
doi:10.1371/journal.pone.0034719.g005
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from chromatin during the normal course of mitosis [30]. We
found that GFP-DC prevented the co-existing full length Brd4 to
dissociate from chromosomes, suggesting that the truncated Brd4
acts as a dominant factor to reinforce its negative effect on full
length Brd4. Although the underlying mechanism is not fully clear,
a direct or indirect interaction between DC and full length Brd4
may explain the dominant negative effect [43,44,45].
Mitotic inhibition observed with DC may have a broader
implication, since some cells express a truncated Brd4 similar to
this truncation [54]. The inability of GFP-DC to dissociate from
chromosomes correlated with abnormal chromosomal segregation
and inhibition of mitotic progression. These data support the
physiological significance of Brd4 release in controlling drug-
induced mitotic stress. Pharmacological and peptide JNK
inhibitors, when added prior to and during nocodazole treatment
led to complete blockade of Brd4 release, which then led to
defective mitotic progression, similar to that seen with DC. These
results support the idea that JNK acts as a critical mediator of
Brd4 release and helps to protect cells against drug-induced
mitotic damage. However, this ‘‘protective’’ activity may create an
adverse condition in some cells, namely increased drug resistance
in cancer chemotherapy, a realistic possibility, given that anti-
mitotic drugs such as taxol and vinblastine are often used for
cancer treatment [1,2].
It has been well documented that anti-tubulin drugs cause
activation of JNK and other MAP kinase pathways [5,6,7]. Recent
evidence indicates that JNK is activated during normal mitosis as
well, and controls mitotic progression [12,14,15]. In some cells,
JNK is reported to mediate histone H3 phosphorylation at serine
10 and activation of Cdk1 to downregulate cyclin B1 [12,15].
Consistent with the role for JNK in mitosis, MKK7, an upstream
kinase that activates JNK is shown to regulate G2/M phase of cell
cycle, and affects cell proliferation and senescence [16]. However,
since Brd4 is released only after drug treatment, not during normal
course of mitosis, Brd4 release is not a part of JNK activation in
normal mitosis, but it occurs as a result of drug-induced JNK
activation. If JNK is activated in normal mitosis, why is Brd4 not
released during normal mitosis? The seeming inconsistency may
be readily explained by a quantitative threshold effect. Anti-
mitotic drugs and other stresses appear to activate JNK at higher
levels than in normal mitosis [9]. It is reasonable to consider that
Brd4 release is triggered only when JNK activity reaches above
a certain threshold. A similar, stress-dependent effect of JNK
activity is reported for activation of apoptotic deal pathway [55]
JNK is activated by many stress signals, which results in
phosphorylation of a large set of substrates, resulting in the
regulation of diverse biological activities [17,18]. In light of the
rapidity with which nocodazole and JNK inhibitors affect Brd4
release, it is possible that Brd4 is a canonical JNK substrate, and
Brd4 is released from chromosomes due to the phosphorylation.
Supporting this possibility, some serine residues in the Brd4 C-
terminal region conform to the predicted phosphorylation sites for
MAP kinases. However, it has been difficult for us to detect
nocodazole induced Brd4 phosphorylation, partly because Brd4 is
constitutively phosphorylated, and nocodazole induced changes, if
they occur, are likely to be quantitative and subtle. In the absence
of definitive results, it remains possible that Brd4 release is
mediated by an indirect mechanism, rather than direct phosphor-
ylation.
It is worth noting here that some of the changes previously
attributed to JNK activation may not hold: a number of studies
utilized SP600125 as a sole inhibitor to assess the function of JNK.
However, this inhibitor is shown to have biological activities
unrelated to JNK [56]. It is of note that activation of JNK
produces seemingly opposite outcomes in some cases [19]: For
example JNK activation is reported to promote apoptosis in some
cases, while it is linked to cell survival in other cells [8,57].
Furthermore, the literature indicates that JNK pathways regulate
mitotic progression in a cell type and context dependent manner:
while JNK is reported to control entry into mitosis, MacKorcle
and Tan reported that JNK controls post-metaphase events, such
as chromosomal segregation, without affecting earlier events such
as cyclin B/Cdk1 activity [12,13,15]. The regulation of post-
metaphase events was attributed to JNK2, not JNK1. This report
is interesting, since defects we observed with DC and JNK
inhibitors also concern anaphase/telophase events rather than
earlier mitotic events. We also found that JNK2–/– MEFs
manifest a greater deficiency in releasing Brd4 and they sustain
greater cell growth inhibition than JNK1–/– cells. These results
suggest that JNK2 plays a more dominant role in regulating Brd4
release and protecting against mitotic stress than JNK1. However,
since JNK1–/– cells were also defective in mitotic progression,
albeit to a lesser degree than JNK2–/– cells, it is likely that both
JNK1 and JNK2 are at work in Brd4 release. This possibility is in
line with the overlapping and distinct roles of the two JNKs
reported before [58]. We noted that the defects found with either
JNK1–/– and JNK2–/– cells were milder than those detected by
DC or JNK inhibitors. This may be due to a compensatory
mechanism activated in these knockout cells that can lessen the
effect of gene disruption. Supporting this possibility, it has been
reported that JNK2–/– cells express increased levels of JNK1 over
wild type cells [59]. Further efforts to study the effect of JNK
reexpression in the JNK–/– cells were unsuccessful, due to
increased cell death (data not shown).
A significant question that arises from this study, which still
awaits further investigation is how Brd4 release leads to protection
against drug induced mitotic stress. A possible answer may lie in
the Brd4’s function during mitosis [30]: we have shown that
during mitosis the bulk of Brd4 binds to the transcription start sites
of many, but not all RNA polymerase II dependent genes. These
transcription start sites carry acetylated histone H3 and H4.
Significantly, Brd4-marked genes are transcribed immediately
after mitosis. It is suggested that orderly Brd4 release is required
for the restoration of mitotic programs which needs to be
established in response to exposure to anti-mitotic drugs, allowing
cells to properly resume transcription in newly devided cells.
In conclusion, the chromatin binding protein Brd4 is released
from chromosomes upon exposure to anti-mitotic drugs in
a manner dependent on the activation of JNK pathway. JNK
activation and Brd4 release may be a part of physiological
responses designed to minimize drug-induced mitotic stress.
Materials and Methods
Ethics Statement
All animal experimentations were conducted in accordance
with NIH and Public Health Service (PHS) policy. All protocols
were approved by The Eunice Kennedy Shriver NICHD Animal
Care and Use Committee (Protocol #08-010).
Cell Culture
P19 embryonal carcinoma cells [22], obtained from American
Tissue Culture Collection were maintained in alpha minimal
essential medium with 10% fetal bovine serum supplemented with




tained from Jackson Laboratories. Mouse embryonic fibroblasts
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embryos of day 14.5 p.c. and cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum and
used within four passages.
Reagents and Plasmids
Nocodazole and other anti-mitotic drugs were purchased from
Sigma-Aldrich. SP600125, SB 203580, PD 98059, U0126, and the
JNK peptide inhibitor, JNKI-1 and control peptide were obtained
from Calbiochem. Cells were treated with these inhibitors prior to
and/or during nocodazole treatment as indicated in Figure
Legends. Full length Flag-Brd4, full length GFP-Brd4 and internal
deletions in pEGFP-C1 vector were described [60].
Transfetion and Live Cell Microscopy
P19 cells (10
5) were incubated in a 10 cm dish overnight and
transfected with 10 mg of full length GFP-Brd4 or GFP-Brd4
deletions by Lipofectamine-Plus (Invitrogen). Twenty four h after
transfection, cells were treated with nocodazole for 4–6 h at
100 ng/ml, mitotic cells were harvested by mitotic shake-off,
stained with Hoechst 33342 and viewed on the Leica TCS-SP2
confocal microscope.
Differential Salt Extraction
Mitotic cells collected after nocodazole treatment were
suspended (5610
4 cells) in polyamine buffer (15 mM Tris-HCl,
pH 7.5, 0.2 mM spermine, 0.5 mM spermidine, 2 mM EDTA,
20 mM KCl, and 0.1% digitonin) with protease inhibitor cocktail
(Roche Diagnostic), homogenized, and centrifuged. Pellets were
incubated with 60, 80, 100, 120 mM of KCl diluted in polyamine
buffer for 30 min at 4uC with gentle rotation. Extracted proteins
were resolved on 4–12% SDS PAGE (Invitrogen), transferred to
Immobilon membrane (Millipore) and immunoblotted with anti-
Brd4 antibody or anti-TFIIB antibody (Santa Cruz). Samples
extracted with 400 mM KCl were used to detect total amounts of
Brd4 and TFIIB.
Immunostaining and Immunoblot Analysis
To localize endogenous Brd4, P19 and JNK–/– cells treated
with anti-mitotic agents were cytospun, fixed, permeabilized and
stained with antibodies for Brd4 and a-tubulin (Sigma-Aldrich)
and counterstained with Hoechst33324 as described [37]. Whole
cell extracts were prepared from 10
6 cells using NP-40 buffer
(50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1.0% NP-40, the
protease inhibitor cocktail and phsophatase inhibitors (50 mM
sodium fluoride, 1 mM sodium orthovanadate, and 0.1 mM
ammonium molybdate)). Twenty mg of cleared extracts were
subjected to immunobot analysis as above. Immunoblot detection
of cyclinB1 was performed as described [37]. Phosphorylated
histone H3 was detected by immunoblot analysis with samples
extracted by RIPA buffer (20 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 1.0% NP-40, 1.0% Na deoxycholate, 0.1% SDS and
protease inhibitor cocktail ) using antibody against serine 10
phopshorylated histone H3 (Millipore).
Supporting Information
Figure S1 A: Localization of Brd4, DNA and alpha-tubulin on
mitotic chromosomes of P19 cells undergoing mitosis. B:
Distribution of Brd4, DNA and alpha-tubulin in P19 cells treated
with nocodazole, paclitaxel and colcemid (each at 100 ng/ml) for
4 hours and untreated control during mitosis.
(TIF)
Figure S2 A: Reloading of Brd4 on mitotic chromosomes after
nocodazole removal. Cells were treated with nocodazole for
4 hours at 100 ng/ml. Mitotic cells were then incubated in fresh
media for indicated times. Cells were immunostained and
counterstained for DNA. B: Association of Brd4 and delta-C
mutant on mitotic chromosomes after nocodazole removal. P19
cells were transfected with GFP alone, GFP full length Brd4 or
GFP delta-C and treated with nocodazole for 4 hours. At 45 min
after nocodazole removal cell were fixed and stained for DNA.
Arrowhead: chromosomal bridge.
(TIF)
Figure S3 P19 cells were cotransfected withFlag-tagged full
length Brd4 along with either GFP alone, GFP-FL Brd4 or GFP-
delta C and treated with nocodazole for 4 hours. Cells were fixed
immunostained for Flag (red), GFP (green) and counterstained for
DNA (blue).
(TIF)
Figure S4 A: JNK inhibitors block nocodazole induced Brd4
release. P19 cells were treated with various inhibitors 30 min or
2 hours prior to the addition of nocodazole. Treatment scheme is
shown on the left. Cells were immunostained for localization of
Brd4 and tubulin and counterstained for DNA. B: Inhibitors alone
do not alter Brd4 localization on Mitotic chromosomes. P19 cells
were treated with SP600125 or vehicle control prior to fixation
and immunostaining. C: later treatment of inhibitors blocks
nocodazole induced Brd4 release. SP600125 was added to cells
3 hours after the start of nocodazole treatment. Treatment scheme
is shown on the left. D: JNKI-1 peptide blocks nocodazole induced
Brd4 release from mitotic chromosomes. P19 cells were incubated
with control or JNKI-1 peptides (5 mM) for 30 min prior to
4 hours nocodazole treatment. After the treatment, cells were
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